This paper provides an update on the clinical and cost-effectiveness of established antiplatelet therapies for secondary stroke prevention.
Informs real-world costs of antiplatelet options for secondary stroke prevention; leaves open which regimen offers best value.
Stroke exacts a huge toll physically, mentally and economically. Antiplatelet therapy is the cornerstone of secondary stroke prevention, and proven drugs available to successfully realize this therapeutic strategy for the long term include aspirin, dipyridamole plus aspirin and clopidogrel. However, government agencies, corporations, health plans and patients desire more information about the clinical- and cost-effectiveness of these established therapies in real-world settings. This paper provides an update on evidence-based secondary stroke prevention with antiplatelet medications, discusses cost-related issues and offers perspective about the future.
No takes yet. Share an insight, caveat, or question.
Rothlisberger et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: